Meaning-Centered-Psychotherapy in the Cancer Setting provides a theoretical context for Meaning-Centered Psychotherapy (MCP), a non-pharmalogic intervention which has been shown to enhance meaning and spiritual well-being, increase hope, improve quality of life, and significantly decrease depression, anxiety, desire for hastened death, and symptom burden distress in the cancer setting. Based on the work of Viktor Frankl and his concept of logotherapy, MCP is an innovative intervention for clinicians practicing in fields of Psycho-oncology, Palliative Care, bereavement, and cancer survivorship. This volume supplements two treatment manuals, Meaning-Centered Group Psychotherapy (MCGP) for Patients with Advanced Cancer and Individual Meaning -Centered Psychotherapy (IMCP) for Patients with Advanced Cancer by Dr. Breitbart, which offer a step-wise outline to conducting a specific set of therapy sessions. In addition to providing a theoretical background on the MCP techniques provided in the treatment manuals, this volume contains chapters on adapting MCP for different cancer-related populations and for different purposes and clinical problems including: interventions for cancer survivors, caregivers of cancer patients, adolescents and young adults with cancer, as a bereavement intervention, and cultural and linguistic applications in languages such as Mandarin, Spanish, and Hebrew.

This volume details basic principles of experimental and computational methods for the study of microRNAs in cancer research and, therefore, provides a firm grounding for those who wish to develop further applications. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, MicroRNA and Cancer: Methods and Protocols, Second Edition aims to ensure successful results in the further study of this vital field

Volume 76 of Advances in Cancer Research continues the series' goal of publishing timely and authoritative reviews in the broad field of cancer research. Ruoslahti begins the volume with a review of fibronectin and its integrin receptors in cancer. Chapter 2 by Ganter and Lipsick discusses Myb and oncogenesis. Biscardi and colleagues present their research on c-Src, receptor tyrosine kinases, and human cancer in Chapter 3. Chapter 4 by Schulz covers epidemiology of Kaposi's sarcoma and associated herpesvirus/human herpesvirus 8. The consensus on synergism between cigarette smoke and other environmental carcinogens in the causation of lung cancer is reviewed by Reif and Heeren in Chapter 5. In Chapter 6, Breivik and Gaudernack discuss perspectives on carcinogenesis and natural selection in the genetics and epigenetics of colorectal cancer. Chapter 7 by Coulie and co-workers concludes the volume with a discussion of anti-tumor immunity at work in a melanoma patient.

Diverse molecular, cellular, and environmental events must all come together to allow the successful formation of secondary cancers, metastases. The second edition of Metastasis Research Protocols, brings together the most up to date versions of the seminal techniques that were presented in the first edition and also includes new techniques that have recently been shown to be important in illuminating the processes underlying this important area of biology. Presented by top scientists, the collection includes a wide spectrum of articles encompassing important key methods and to introduce new methods which are making an impact in the area of metastasis research. Volume 1 includes key cellular and molecular techniques relevant to the exploration of cancer cells and tissues, the focus is on the tools that have been shown to be helpful in unravelling the molecular processes important in cancer metastasis. Written in the highly successful Methods in Molecular Biology (TM) series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Metastasis Research Protocols, Second Edition seeks to aid scientists in the further study of new methods in the area of metastasis research.

This book explores various applications of deep learning to the diagnosis of cancer,while also outlining the future face of deep learning-assisted cancer diagnostics. As is commonly known, artificial intelligence has paved the way for countless new solutions in the field of medicine. In this context, deep learning is a recent and remarkable sub-field, which can effectively cope with huge amounts of data and deliver more accurate results. As a vital research area, medical diagnosis is among those in which deep learning-oriented solutions are often employed. Accordingly, the objective of this book is to highlight recent advanced applications of deep learning for diagnosing different types of cancer. The target audience includes scientists, experts, MSc and PhD students, postdocs, and anyone interested in the subjects discussed. The book can be used as a reference work to support courses on artificial intelligence, medical and biomedicaleducation.

The aim of this book will be to contribute to the education of a new generation of experts in urology, molecular biology, pathology and oncology, offering them sufficient knowledge in basic and translational research to be fluency in the web of interacting networks playing a role in prostate cancer development, progression, metastasis and drug-resistance.The volume will cover the latest innovative researches in prostate cancer, with particular emphasis to the state-of-the-art analysis technologies that are essential for the accurate identification of molecular targets for disease diagnosis, molecular mechanisms of tumorigenesis, markers for susceptibility, molecular-based prognostic prevision, characterization of biomarkers of drug efficacy and drug resistance, validation of new therapeutics and diagnostics. Current advancements on the intersecting data concerning transcriptomes, proteomes, the molecular techniques referred as "omes," will be reported and discussed.

Aegean Conferences is an independent, nonprofit, educational organization directed and managed by the scientific community. The board is made up of nine researchers/scientists in various disciplines from Harvard, Brown, University of Pennsylvania, UCSD, Princeton, Biovista and the Foundation for Biomedical Research Academy of Athens. The board both invites and approves unsolicited proposals for Conferences in all fields of Science, Engineering, Arts, and Humanities. The purpose of the Conferences is to bring together individuals with common interests to examine the emerging and most advanced aspects of their particular field.

The Symposium on Ovarian Cancer: State of the Art and Future Directions intends to bring together international experts interested in the development of novel diagnostic, prognostic and therapeutic tools for ovarian cancer. The meeting will function as a think tank where clinicians, translational and basic scientists, and parties from the biotechnology and pharmaceutical industry will get together to review recent advances in clinical research and translational science in ovarian cancer and define areas of future research opportunities and priorities.

This book highlights the wide applications of nanomaterials in healthcare and environmental remediation. Presenting nano-based materials that positively influence the growth and proliferation of cells present in soft and hard tissue and are used for the regeneration bone tissue and/or suppression of cancer cells, it also discusses the natural products that can be incorporated in nanofibers for the treatment of cancer. Further, it describes the use of blending and functionalization to produce chitosan nanofibers for biomedical applications, and reviews the role of plasma-enhanced gold nanoparticles in diagnostics and therapeutics. Lastly, the book also introduces various nanotechnology approaches for the removal of waste metabolites in drinking water, and explores the emerging applications of nanorobotics in medicine. Given its scope, this book is a valuable resource for scientists, clinicians, engineers and researchers aiming to gain a better understanding of the various applications of nanotechnology.

This book reviews the potential of next-generation sequencing (NGS) in research on and management of colorectal cancer (CRC), a leading cause of death worldwide and one of the most biologically and clinically heterogeneous cancers. It critically discusses findings from recent large-scale studies, clinical trials and meta-analyses and offers an introduction to the management of CRC in the era of precision medicine. In CRC, dozens of driver and passenger mutations are associated with the malignant transformation of epithelial cells. Consequently, the book discusses recent advances in our understanding of the genetics of CRC as a biomarker, the advent of NGS technologies in modern genomics, and the impact of NGS technology on the management of CRC. Furthermore, it highlights the potential of NGS in the context of liquid biopsy and single-cell sequencing in CRC, as well as its role in shedding light on the link between gut microbiota, immune-checkpoint blockade and CRC. The book concludes with a chapter on the limitations and cost-effectiveness of NGS in CRC. Given its scope, the book will appeal to all those interested in learning about the potential of NGS in advancing CRC research and patient care.

The MD Anderson Solid Tumor Oncology series presents the most cutting-edge surgical treatment and medical therapy for specific sites. Each year, more than 26,000 people are diagnosed with pancreatic cancer, also called a "silent" disease because it does not usually exhibit early symptoms. This volume defines the current standard on multimodality care: surgery, chemotherapy, immunotherapy, gene therapy, radiotherapy, and a review of the latest research and clinical trials. It includes sections on: epidemiology/molecular biology, inherited pancreatic cancer syndromes, staging, various surgical techniques and outcomes, multimodality therapy and emerging and future therapies. The individual chapters focus on specific topics to produce a reference work of value to those interested in pancreatic cancer from a clinical and translational research perspective. A must-have for surgical oncologists and general surgeons.

Based on the most novel approaches and cutting-edge clinical and scientific information regarding radionuclide imaging and therapies for neuroendocrine tumors, this clinical guidebook represents a unique collaborative effort between endocrinologists, nuclear physicians, oncologists, surgeons, physicists, radio-pharmacists and geneticists. It begins with the embryology, classification and molecular genetics of gastroenteropancreatic neuroendocrine tumors and carcinoids, chromaffin cell tumors, and MEN1- and MEN2-related tumors. Following a chapter on radiopharmaceuticals in neuroendocrine imaging, it turns to the physics and technology of current and cutting-edge radiology, including SPECT/CT and PET/CT and PET/MR. Discussing of radionuclide imaging covers the tumors mentioned above, as well as pulmonary and thymic neuroendocrine tumors and medullary thyroid carcinoma. A presentation of radionuclide therapies follows, including 131I-MIBG therapy, somatostatin receptor-based therapy, and alpha radionuclide therapy, as well as the role of nanoparticles. Comprehensive and up-to-date, Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors will assist and guide physicians who encounter patients with these conditions, either from a diagnostic or therapeutic standpoint, and particularly emphasizes the current and emerging medical devices and imaging and therapeutic options.

Prominent investigators and clinicians summarize in a balanced blend of fundamental science, basic research, experimental therapeutics, and early clinical experiences, what is known about oncogenes and oncogenesis, and describe how that knowledge can be used to treat the cancer. The contributors explain how, why, and under what conditions certain proteins acquire the ability to transform eukaryotic cells, and detail the crucial biological consequences of this oncogenic transformation, particularly for cellular mitogenesis, survival, differentiation, migration, proteolysis, or angiogenic competence. Their articles thoroughly explicate the premises, principles, techniques, and approaches to oncogene targeting in various types of human cancer by using signal transduction inhibitors, immunological targeting methods, and antisense gene therapy.

This timely desk reference focuses on marine-derived bioactive substances which have biological, medical and industrial applications. The medicinal value of these marine natural products are assessed and discussed. Their function as a new and important resource in novel, anticancer drug discovery research is also presented in international contributions from several research groups. For example, the potential role of Spongistatin, Apratoxin A, Eribulin mesylate, phlorotannins, fucoidan, as anticancer agents is explained. The mechanism of action of bioactive compounds present in marine algae, bacteria, fungus, sponges, seaweeds and other marine animals and plants are illustrated via several mechanisms. In addition, this handbook lists various compounds that are active candidates in chemoprevention and their target actions. The handbook also places into context the demand for anticancer nutraceuticals and their use as potential anti-cancer pharmaceuticals and medicines. This study of advanced and future types of natural compounds from marine sources is written to facilitate the understanding of Biotechnology and its application to marine natural product drug discovery research.

This is a practical guide to the design, conduction, analysis and reporting of clinical trials with anticancer drugs. It includes coverage of basic biostatistics for the clinical trialist, and fundamental concepts in clinical pharmacology.

This text is the only book of its kind to provide specific guidance applicable to limited resource settings and builds up from the foundation of general practitioner or general pediatrician competence. Written and edited by leaders in the field, this manual educates physicians on the essential components of the discipline, filtered through the experience of specialists from developing countries, with immediate applicability in the specific healthcare environment in these countries. Typically, manuals of pediatric hematology-oncology are written by specialists from high-income countries, and usually target an audience with a sub-specialist level of training, often assisted by cutting-edge diagnostic and treatment facilities. However, approximately 80% of new cases of cancer in children appear in mid- and low-income countries. Almost invariably, general practitioners or general pediatricians without special training in oncology will look after children with malignancies who enter the health care system in these countries. The diagnostic facilities are usually limited, as are the treatment options. The survival figures in these conditions are somewhere below 20%, while in high-income countries they are in the range of 80% for many childhood cancers. This book includes simplified therapy protocols, pain therapy and palliation, as well as ward procedures such as bone marrow aspiration/biopsies, intravenous therapy and chemotherapy drugs mixing. It provides an overview of pediatric cancer epidemiology, cancer registration and organizing support networks and features the management of cancers with associated pathology like AIDS, malnutrition, malaria and tuberculosis.

Despite advances in detection and treatment, cancer remains a source of pain and distress to patients and of complex challenges to the loved ones caring for them. The trend toward shorter hospital stays in particular has increased the physical, psychological, and financial burden on caregivers, often leading to adverse effects on patients.

"Cancer Caregiving in the United States" illuminates these complex concerns with authoritative detail. This wide-ranging volume provides a comprehensive survey of cancer-related issues, including those affecting the care triad (patients-family members- professionals) and quality of care as well as the numerous physical, emotional, and financial challenges that caregivers may need to confront. Sources of caregiver difficulty at each stage of the disease, from diagnosis to end of life, are explored. Each chapter analyzes its topic in terms of practice, research, education, and policy, providing a wealth of literature reviews, assessment and care models, interventions, and recommendations for future study and practice.

Coverage includes:

Caregiving issues for cancer patients with long-term, short-term, and intermittent needs.Family caregivers as members of the treatment team.The impact of health disparities on caregivers.Cancer care policy and advocacy.End-of-life issues for cancer caregivers.Legal, financial, and ethical issues.

"Cancer Caregiving in the United States" is a core reference for researchers, professionals/scientist-practitioners, and graduate students in such caregiving fields as clinical psychology, social work, nursing, public health and medicine, social policy, and educational policy."

Pancreatic cancer is the fourth leading cause of cancer death in the United States. Every year, about 33,700 people in the United States will be diagnosed with pancreatic cancer and over 32,000 patients will die from the disease. The median survival of patients with advanced pancreatic cancer is about 6-months. This dismal picture of pancreatic cancer is mainly due to the lack of early diagnosis and effective treatment for patients with advanced disease. To increase the survival rate of pancreatic cancer patients, better tumor markers for diagnosis and new molecular targets for drug development are desperately needed. A lot of effort has been made in searching for pancreatic cancer-causing genes or genes associated with progression of malignant behavior in pancreatic cancer. As a result, alterations in the expression of several cancer-related genes have been identified in pancreatic tumors. The identification and characterization of these cancer-related genes have significantly increased our understanding of pancreatic cancer development, but unfortunately the treatment of pancreatic cancer has not advanced as much in the past 20 years.

Over the past decade, tremendous advances have been made in the field of cancer drug discovery, particularly, in the area of molecular and genetic models and technologies. Many of those advanced models and technologies have been applied to the drug discovery processes for pancreatic cancer. In this book, a team of experts will describe the latest development in the application of these models and technologies in pancreatic cancer. The authors include basic researchers as well as clinicians who work in the front-line of the war against pancreatic cancer and have the first-hand experience on these cutting-edge tools and techniques. The book can be divided into two general areas: 1) model systems and 2) genomics and proteomics tools. In recent years there have been a lot of advances in the model systems for pancreatic cancer, including the further characterization of normal and cancerous pancreatic cell lines, the establishment of transgenic mouse models that recapitulate the initiation and progression of human pancreatic cancer, the development of a new xenograft model system for the evaluation of novel agents, and the establishment of a zebrafish pancreatic cancer model. The first four chapters of the book will be devoted to these models. The advances in genomics and proteomics research have made a major impact in cancer drug discovery. A number of these omics-based tools and techniques have been applied in the pancreatic cancer drug discovery. Chapters 5-9 of the book will discuss techniques for genome-wide examination of gene expression, copy number, methylation, function and regulation. Chapters 10-11 will discuss in situ techniques for studying chromosomal and gene copy number abnormalities as well protein expression changes in cancer samples. Chapters 12-14 will focus on techniques for global examination of protein expression levels in biospecimens obtained from pancreatic cancer patients. Cancer drug discovery has become more and more target-centric. "

This volume details standard techniques for the characterization of urothelial carcinoma as well as methods to investigate mechanisms of carcinogenesis. Chapters guide readers on cellular and animal models for urothelial carcinoma and related diseases, molecular analyses from body fluids, and new approaches to therapy. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Urothelial Carcinoma: Methods and Protocols hopes that the techniques described in this volume will contribute to the current upturn in research on urothelial carcinoma and to the application of its results in clinical practice.

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.

Although pancreatic cancer is one of the most serious forms of cancers, the outlook for patients could be improved. The lack of clinical symptoms of early, surgically removable disease most often limits curative treatment options. The aggressive tumor cell biology, leading to a locally advanced nature of the disease and to early metastases, allows curative resection in only 20% of patients at the time of diagnosis. Patients are therefore often faced with a dreadful prognosis from a state of almost full physical health. Furthermore, because there is a high recurrence rate after curative resection, treatment of this tumor entity becomes a great challenge.

This book gives insight into the current understanding of the management of pancreatic cancer and considers recent findings in cancer research. It provides answers to questions of how to know when cancer is respectable, how to proceed when the diagnosis comes too late for a curative approach, and how to assess different study results. Moreover, it highlights new upcoming therapeutic options and experimental approaches, which might further improve the future prospects for patients with pancreatic adenocarcinoma.

Multivariate analysis is a mainstay of statistical tools in the analysis of biomedical data. It concerns with associating data matrices of n rows by p columns, with rows representing samples (or patients) and columns attributes of samples, to some response variables, e.g., patients outcome. Classically, the sample size n is much larger than p, the number of variables. The properties of statistical models have been mostly discussed under the assumption of fixed p and infinite n. The advance of biological sciences and technologies has revolutionized the process of investigations of cancer. The biomedical data collection has become more automatic and more extensive. We are in the era of p as a large fraction of n, and even much larger than n. Take proteomics as an example. Although proteomic techniques have been researched and developed for many decades to identify proteins or peptides uniquely associated with a given disease state, until recently this has been mostly a laborious process, carried out one protein at a time. The advent of high throughput proteome-wide technologies such as liquid chromatography-tandem mass spectroscopy make it possible to generate proteomic signatures that facilitate rapid development of new strategies for proteomics-based detection of disease. This poses new challenges and calls for scalable solutions to the analysis of such high dimensional data. In this volume, we will present the systematic and analytical approaches and strategies from both biostatistics and bioinformatics to the analysis of correlated and high-dimensional data.

A cutting-edge review of how derangements in the hormonal and growth factor mechanisms controlling normal mammary development lead to breast cancer. Drawing on the multidisciplinary expertise of leading authorities, the book highlights the roles of oncogenes and tumor suppressor genes, spelling out the importance of autocrine/paracrine loops (e.g., stromal epithelial interactions) in supporting breast cancer cell proliferation and the progression to hormone independence. The book's many prominent contributors also illuminate significant recent advances in the biochemistry and physiology of hormone receptors and review the state-of -the-art in the endocrine therapy of breast cancer. Endocrinology of Breast Cancer provides a unique integrated overview of the most significant basic and clinical developments concerning the hormonal aspects of breast cancer.

This volume gives a general summary of the current understanding of lymphatic metastasis and the possibilities of more specific detection of lymph node metastasis. It describes in detail the procedure of sentinel lymph node detection in urogenital tumors, neck and thyroid tumors, malignant melanoma, gastric and colorectal cancer and tumors of the breast. The potential and limitations of this new method are discussed. This book provides comprehensive insight into a both clinically and scientifically important new field which is bringing about a marked improvement in the treatment of malignant tumors.

Despite the major developments in the therapeutic armamentarium for the treatment of infection, the morbidity and mortality of this complication remains very high in patients with compromised defences. Cancer and its treatment represents a major predisposing condition to a variety of infections. These adverse events are still with us, in spite of much progress in the therapy of infectious disease, since cancer therapy is becoming more aggressive, yet further lowering the host's capacity to cope with infections. Moreover, the pathogens adapt effectively to drugs, and at a pace that might outrun industry's capability to produce new agents. Finally, new pathogens are appearing as a consequence of both selection and severe immunosuppression. Infection is so common among cancer patients that its diagnosis and management represent a daily challenge to all oncologists, who must continually strive to keep abreast of developments in the area. The present comprehensive review of the most crucial and challenging aspects of the infectious complications in cancer patients will help them to do just that.